報價延遲最少15分鐘:2026/04/29 07:45 EDT
盤前時段
|
||||
|
7.19 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.18
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.66/-3.12
|
|
企業價值
344.78M
|
| 資產負債 |
|
每股賬面淨值
1.46
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
35.26M
|
|
每股收益
0.44
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing theirability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States. |
